FindMyKOL

Srinivas Murali, MD

Basic profile

Allegheny Health Network

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPittsburgh, PA · NortheastSpecialtyAdvanced Heart Failure and Transplant CardiologyFocusCardiology
Last active 2024FindMyKOL type: RegionalLatest publication2022Online presenceNot yet checkedPayments2021 onwardNIH funding2015–2017Why? →

Srinivas Murali is a Cardiology physician affiliated with Allegheny Health Network. OpenAlex indexes 257 publications with 11,832 citations (h-index 48).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
257publications

Publications indexed by OpenAlex. Counts exclude supporting files.

11,832citations

Citations across these publications.

48h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
12companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2015–2017

Federally funded research awards.

View funding ↓

Industry payments

12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Pfizer
    Program year20241 paymentResearch
    $3,525
  • Impulse Dynamics (USA) Inc.
    Program year20241 payment
    $14
  • CVRx
    Program year20236 paymentsResearch
    $5,750
All 25 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    75.2%
    Beta blocker17.4%
    Carvedilol58%Metoprolol Succinate31%Metoprolol Tartrate11%
    Part D<11 patients
    Angiotensin receptor-neprilysin inhibitor (ARNI)12.8%
    Entresto100%
    Part D≥22 patients

    + 8 more classes in this area

  • Metabolism & gastrointestinal

    13.1%
    SGLT2 inhibitor11.3%
    Jardiance87%Farxiga13%
    Part D<11 patients
    Potassium supplement1.7%
    Potassium Chloride100%
    Part D<11 patients
  • Blood & clotting

    9.4%
    Factor Xa inhibitor5%
    Eliquis100%
    Part D≥14 patients
    Prostacyclin Receptor Agonist2.4%
    Uptravi100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B), 202213.8% facility · 86.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2015–2017 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”